Marcus Turnley, PA
Surgical · Paducah, KYNPI 1497742670
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,473 of the $2,387 with a category attached, or 61.7%. AbbVie accounts for 79.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $2,075 and has fallen 98.8% since, to $24 in 2024.
Across 25 payments — averaging $95.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Integra Lifesciences Corporation$217
- Merck$70
- Regeneron Healthcare Solutions, Inc.$59
- Boston Scientific$37
- Pacira Pharmaceuticals Incorporated$23
- plus $80 from 5 others
What the payments were for
- Travel & lodging$1,47362%
- Food & beverage$91538%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $1,901 |
| Integra Lifesciences Corporation | 3 | $217 |
| Merck | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 1 | $59 |
| Boston Scientific | 2 | $37 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Innocoll Pharmaceuticals Limited | 1 | $23 |
| Merit Medical Systems Inc | 1 | $15 |
| TELA Bio, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE SALINE-FILLED BREAST IMPLANTS$2,727
- REVOLVE$1,073
- SURGIMEND$117
How this compares
$2,387 in reported general payments places this provider in the 85th percentile of 72 surgical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 114 | $2,776 |
| Tamoxifen Citrate | 72 | $1,940 |
| Montelukast Sodium | 199 | $1,856 |
| Anastrozole | 11 | $389 |
| Mupirocin | 63 | $376 |
| Raloxifene Hcl | 11 | $269 |
| Doxycycline Hyclate | 32 | $212 |
| Nystatin | 11 | $185 |
Paid to pharmacies, not to this prescriber.
Other surgical in Paducah
- William MeadorsLexington$16K
- Mark GrandonLouisville$9K
- Adam LocklarLexington$4K
- Jamie BlackLexington$4K
- David YeagerLouisville$4K
- Korey PlewinskiLouisville$4K
- Hannah JohnsonBardstown$4K
- Rachel WeaverLexington$3K
- Elizabeth KordikLouisville$3K
- Michael DuganLexington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.